Royalty Report: Drugs, Disease, Bacterial Infection – Collection: 266736

License Grant

Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property

Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use

Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

License Grant

Licensor (a nonprofit, tertiary, hospital and multispecialty academic health science center) hereby grants to Licensee, and Licensee hereby accepts from Licensor, the exclusive license, with the right to grant sublicenses, under and to the Patent Rights and Technical Information during the term of this Agreement to conduct research in the Field of Use and to make, have made, use, develop, import, have imported, export, have exported, offer for sale, or have offered for sale, sell and/or have sold Licensed Products and Licensed Technology Products in the Field of Use in the Territory. The foregoing grant of exclusivity is made expressly subject to the following

(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertain to the manufacture of products within the United States;

(b) All applicable rules of the Funding Agencies which have provided funding to Licensor or to any of its employees (including any of the Inventors) for the development of the Patent Rights and Technical Information; and

(c) The following non-exclusive rights to the Patent Rights and Technical Information, which are retained by Licensor within the Field of Use
(i)  the right to submit for publication the scientific findings from research conducted by or through Licensor or its investigators (including the Inventors) related to the Patent Rights and the Technical Information; and
(ii)  the right (A) to use any tangible or intangible information contained in the Patent Rights or the Technical Information or any Improvements (so long as Licensor shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for Licensor’s internal non-commercial scientific, research, internal teaching, non-profit clinical research and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).

(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights, Technical Information and Improvements outside of the Field of Use are retained by Licensor. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of Licensor other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.

License Property

Patent Rights
6,861,053 – Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

6,805,852 – Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

7,056,686 – Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth

Field of Use

Licensed Products relate to new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes.

Archaea is a group of primitive prokaryotes that based on their distinct characteristics form a separate domain from bacteria and eukaryotes. Bacteria are single-celled primitive organisms that form a domain of organisms diverse in shape, size, structure, and even habitats.

License Grant

The agreement is for products containing crofelemer or any derivative thereof obtained from any species of the Croton lechleri plant.

License Property

The product is defined as all products for the treatment, maintenance or improvement of human health which are prescription medicines, botanicals, dietary supplements sold for the treatment of diarrhea, Irritable Bowel Syndrome (IBS) or herpes.

Field of Use

This agreement is for the pharmaceutical industry.